Aortopathy β-アミノプロピオニ トリルによる大動脈瘤と解離のマウスモデルでのマイクロ CT 定量分析

Executive Industry Relevance

Quantitative micro-CT analysis of aortopathy in mouse models enables precise, reproducible measurement of vascular pathology, supporting early-stage target validation and mechanistic de-risking in cardiovascular drug discovery. This imaging-driven workflow enhances predictive confidence for translational research by providing standardized, quantitative endpoints for aortic aneurysm and dissection models. The approach is positioned to inform portfolio triage and risk-adjusted advancement decisions in preclinical vascular biology programs.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables quantitative assessment of vascular remodeling and disease progression in genetically or chemically induced models.
• Supports mechanistic de-risking by correlating vessel size changes with molecular interventions.
• Provides standardized criteria for defining aneurysm thresholds, improving target validation rigor.

Screening & Assay Development

• Facilitates preparation of validated vascular models for downstream imaging-based screening.
• Delivers reproducible, quantitative vessel diameter measurements for assay standardization.
• Enables cross-study comparison and scalability for compound evaluation in vascular disease models.

Translational & Preclinical Research

• Aligns preclinical endpoints with clinically relevant vascular pathology, supporting translational biomarker strategies.
• Provides continuity from discovery through preclinical validation by enabling robust, quantitative imaging outputs.
• Reduces biological ambiguity in preclinical decision-making for aortic disease programs.

Pipeline & Workflow Integration

This micro-CT imaging protocol integrates into the discovery-to-preclinical continuum, bridging early mechanistic studies with translational model validation for aortic disease research.

• Discovery Biology: Supports hypothesis testing on vascular remodeling and disease mechanisms in mouse models.
• Screening: Provides quantitative, reproducible vessel measurements for assay readiness and cross-study comparability.
• Analytics: Enables statistical analysis of aortic diameters and aneurysm frequency across experimental groups.
• Translational Research: Aligns preclinical imaging outputs with clinical vascular endpoints for biomarker development.
• Enterprise Reuse: Establishes a standardized imaging workflow adaptable to other vascular beds and disease models.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in vascular target validation.
• Operational Value: Delivers standardized, reproducible, and scalable imaging protocols for cross-team adoption.
• Strategic Value: Improves go/no-go decisions and capital efficiency by providing robust quantitative endpoints.
• Portfolio Impact: Enables risk-adjusted prioritization and advancement of vascular disease programs.

Implementation Considerations

• Requires expertise in animal surgery, vascular perfusion, and micro-CT imaging analysis.
• Demands access to micro-CT instrumentation and radiopaque contrast agents.
• Necessitates rigorous cross-team standardization of imaging and measurement protocols.
• Adaptable to various vascular beds and disease models with protocol optimization.
• Non-survivability of the procedure limits longitudinal studies in the same animal.

Biopharma FAQs